作者回复。
The Authors Respond.
机构信息
Western University of Health Sciences College of Pharmacy
Western University of Health Sciences College of Pharmacy.
出版信息
J Manag Care Spec Pharm. 2020 Mar;26(3):335-336. doi: 10.18553/jmcp.2020.26.3.335.
Abstract
Funding for the original study referred to in this letter was received through the PhRMA Foundation Value Assessment Challenge Award. The authors have no conflicts of interest to declare.
摘要
本函所提到的原始研究的资金来自 PhRMA 基金会价值评估挑战赛奖。作者声明不存在利益冲突。
相似文献
1
The Authors Respond.
J Manag Care Spec Pharm. 2020 Mar;26(3):335-336. doi: 10.18553/jmcp.2020.26.3.335.
2
A review of economic evaluation in osteoporosis.
Arthritis Care Res. 1999 Dec;12(6):425-34. doi: 10.1002/1529-0131(199912)12:6<425::aid-art11>3.0.co;2-a.
3
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis.
Osteoporos Int. 2002 Nov;13(11):841-57. doi: 10.1007/s001980200117.
4
Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award.
J Manag Care Spec Pharm. 2021 Sep;27(9-a Suppl):S2-S3. doi: 10.18553/jmcp.2021.27.9-a.s2.
5
Patient-Level Modeling Approach Using Discrete-Event Simulation: A Cost-Effectiveness Study of Current Treatment Guidelines for Women with Postmenopausal Osteoporosis.
J Manag Care Spec Pharm. 2019 Oct;25(10):1089-1095. doi: 10.18553/jmcp.2019.25.10.1089.
6
Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award.
J Manag Care Spec Pharm. 2021 Sep;27(9-a Suppl):C2-C3. doi: 10.18553/jmcp.2021.27.9-a.c2.
7
Treatment of established osteoporosis: a systematic review and cost-utility analysis.
Health Technol Assess. 2002;6(29):1-146. doi: 10.3310/hta6290.
8
The need for microsimulation to evaluate osteoporosis interventions.
Osteoporos Int. 2005 Apr;16(4):353-8. doi: 10.1007/s00198-004-1826-8. Epub 2005 Jan 11.
9
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.
Osteoporos Int. 2007 Jan;18(1):9-23. doi: 10.1007/s00198-006-0257-0. Epub 2006 Nov 9.
10
Proposal for capturing patient experience through extended value frameworks of health technologies.
J Manag Care Spec Pharm. 2021 Jul;27(7):936-947. doi: 10.18553/jmcp.2021.27.7.936.
本文引用的文献
1
Patient-Level Modeling Approach Using Discrete-Event Simulation: A Cost-Effectiveness Study of Current Treatment Guidelines for Women with Postmenopausal Osteoporosis.
J Manag Care Spec Pharm. 2019 Oct;25(10):1089-1095. doi: 10.18553/jmcp.2019.25.10.1089.
2
Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
Semin Arthritis Rheum. 2019 Oct;49(2):184-196. doi: 10.1016/j.semarthrit.2019.01.006. Epub 2019 Jan 10.
3
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.
Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42. doi: 10.4158/EP161435.GL.
4
Clinician's Guide to Prevention and Treatment of Osteoporosis.
Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15.
5
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
JAMA. 2006 Dec 27;296(24):2927-38. doi: 10.1001/jama.296.24.2927.
6
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
J Bone Miner Res. 2005 Sep;20(9):1507-13. doi: 10.1359/JBMR.050501. Epub 2005 May 2.
7
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Arch Intern Med. 2004 Oct 11;164(18):2024-30. doi: 10.1001/archinte.164.18.2024.
Zotero 插件